MaxCyte, Inc.
("MaxCyte" or the "Company")
Total Voting Rights
Gaithersburg, Maryland - 2 June 2021: MaxCyte (LSE: MXCT, MXCN), the global cell-based medicines and life sciences company, announces that pursuant to its block admission facility, details of which were announced on 2 May 2017, it has recently issued 34,722 shares of common stock, $0.01 par, of the Company ("Common Stock") in satisfaction of the exercise of share options.
The new Common Stock will rank pari passu with the existing shares of common stock of the Company. The total issued stock capital of the Company following the recent issue of the new Common Stock is 84,719,345 shares of Common Stock. Shareholders in the Company may use this figure as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the stock capital of the Company.
The number of unrestricted shares of Common Stock trading under the symbol 'MXCT' is 84,389,345 and the number of restricted shares of Common Stock trading under the symbol 'MXCN' will be 330,000.
For further information, please contact:
|
|
|
|
MaxCyte Inc.
Doug Doerfler, Chief Executive Officer
Ron Holtz, Chief Accounting Officer
|
+1 301 944 1660
|
|
Nominated Adviser and Joint Corporate Broker
Panmure Gordon
Emma Earl
Freddy Crossley
Corporate Broking
Rupert Dearden
|
+44 (0)20 7886 2500
|
|
Joint Corporate Broker
Numis Securities Limited
James Black
Duncan Monteith
|
+44 (0)20 7260 1000
|
|
Joint Corporate Broker
Stifel Nicolaus Europe Limited
Healthcare Investment Banking
Nicholas Moore / Ben Maddison / Samira Essebiyea
Corporate Broking
Nick Adams
|
+44 (0) 20 7710 7600
|
|
|
About MaxCyte
MaxCyte is a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization. MaxCyte's existing customer base ranges from large biopharmaceutical companies, including all of the top 10, and 20 of the top 25, pharmaceutical companies based on 2020 global revenue, to hundreds of biotechnology companies and academic centers focused on translational research. MaxCyte has granted 13 strategic platform licences to commercial cell therapy developers. Including these strategic platform licences, MaxCyte has granted research and clinical licences with academic and industry customers covering over an estimated 140 programs, and clinical licences with academic and industry customers covering over an estimated 100 programs being developed for use in humans. MaxCyte was founded in 1998 and is headquartered in Gaithersburg, Maryland, US. For more information, visit www.maxcyte.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the
United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the
London Stock Exchange use the personal data you provide us, please see our
Privacy Policy.
END
